CAC
TARS icon

Cowen and Company’s Tarsus Pharmaceuticals TARS Stock Holding History

Cowen and Company’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,197,385
Closed -$72.3M – 283
2024
Q3 		$72.3M Hold
2,197,385
– – 2.43% 10
2024
Q2 		$59.7M Buy
2,197,385
+74,855
+4% +$2.52M 1.64% 11
2024
Q1 		$77.2M Buy
2,122,530
+211,131
+11% +$6.21M 2.99% 6
2023
Q4 		$38.7M Buy
1,911,399
+114,626
+6% +$1.91M 2.54% 6
2023
Q3 		$31.9M Sell
1,796,773
-202,610
-10% -$3.59M 2.23% 7
2023
Q2 		$36.1M Buy
+1,999,383
New +$31.8M 2.99% 8
2022
Q4 		– Sell
-522,329
Closed -$8.94M – 729
2022
Q3 		$8.94M Sell
522,329
-12,195
-2% -$194K 0.86% 28
2022
Q2 		$7.8M Hold
534,524
– – 0.75% 32
2022
Q1 		$8.99M Buy
534,524
+20,235
+4% +$376K 0.87% 30
2021
Q4 		$11.6M Hold
514,289
– – 1.05% 19
2021
Q3 		$11.1M Hold
514,289
– – 0.53% 29
2021
Q2 		$14.9M Buy
+514,289
New +$16.1M 0.78% 21

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Cowen and Company's TARS Position: Q4 2024 in Review

Cowen and Company sold out of Tarsus Pharmaceuticals (TARS) in Q4 2024, closing a stake of 2,197,385 shares — an estimated $72.3M sold.

Cowen and Company first reported a position in TARS in Q2 2021 and held it in 12 quarters. The position peaked at $77.2M in Q1 2024. 195 funds tracked by Wall St. Rank hold TARS as of Q4 2024.

  • Cowen and Company reported no remaining Tarsus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 2,197,385 Tarsus Pharmaceuticals shares in Q4 2024, an estimated $72.3M.
  • Cowen and Company first reported a position in Tarsus Pharmaceuticals in Q2 2021 and held it in 12 quarters.
  • Cowen and Company's Tarsus Pharmaceuticals position peaked at $77.2M in Q1 2024.
  • 195 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.